ACTRN12614000090617已完成1 期
Comparative, randomized, single dose, three-period, cross-over open label study to evaluate the pharmacokinetic parameters of a new formulation of paracetamol and phenylephrine tablets (Maxiclear) relative to an oral administration of fixed dose combination of paracetamol 1000 mg and phenylephrine 10 mg and relative to an oral administration of phenylephrine 10 mg tablets alone, in healthy adults under fasting conditions
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 40 Years（—）
- 性别
- All
入选标准
- •Healthy volunteers
排除标准
- •pregnancy, nursing, drug abuse, smoking > 10 cigarettes per day, excess alcohol intake, prescription drugs within 14 days of the study, participating in another trial within 80 days, clinically significant abnormal lab tests
研究者
相似试验
已完成
1 期
Pharmacokinetic study of acetaminophen and ibuprofen oral formulation, in healthy volunteers, fasting conditionsPain reliefAnaesthesiology - Pain managementACTRN12616000316404AFT Pharmaceuticals Ltd.30
已完成
1 期
Pilot study to evaluate and compare the pharmacokinetic parameters of different doses of phenylephrine hydrochloride combined with paracetamol in 12 healthy adults under fasting conditions.ACTRN12615000740594AFT Pharmaceuticals Ltd.12
已完成
不适用
Randomized, open-label, single-dose, three-treatment, three-period, six-sequence, cross-over design phase 1 clinical trial to compare the pharmacokinetics and safety/tolerability after oral administration of Mytonin Tab. 25mg and IY-HCR17 in healthy volunteersDiseases of The genitoruinary systemKCT0003368Seoul National University Bundang Hospital36
尚未招募
不适用
A study to assess the bio availability of BCO-5 in comparison with unformulated extracts in healthy volunteers.CTRI/2022/11/047533Akay Natural Ingredients Pvt Ltd
已完成
不适用
A single dose, randomized, three arm, two-way, cross-over study to assess the effect of food on the pharmacokinetics of the commercial NOMAC-E2 tablet formulation and of the phase 3 pivotal clinical batches (Protocol No. P06456)Gecombineerde orale hormonale anticonceptiebirth controlContraceptiveNL-OMON35968Schering-Plough60